

ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Bonqat 50 mg/ml oral solution for cats

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

Active substance:

Pregabalin 50 mg

Excipient:

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Sodium benzoate (E211)	2 mg
Ethyl maltol	
Hydrochloric acid, dilute (for pH adjustment)	
Sodium hydroxide (for pH adjustment)	
Purified water	

Clear, colourless to slightly reddish solution.

3. CLINICAL INFORMATION

3.1 Target species

Cats.

3.2 Indications for use for each target species

Alleviation of acute anxiety and fear associated with transportation and veterinary visits.

3.3 Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

3.4 Special warnings

None.

3.5 Special precautions for use

Special precautions for safe use in the target species:

The safety of the veterinary medicinal product has not been established in cats weighing less than 2 kg, younger than 5 months and older than 15 years. Use only according to the benefit-risk assessment by the responsible veterinarian.

The safety of the veterinary medicinal product has only been established in healthy cats or those with mild systemic illness. It has not been established in animals with moderate or severe systemic disease e.g. moderate to severe renal, liver, or cardiovascular disease. Use only according to the benefit-risk assessment by the responsible veterinarian.

Always assess the cat's health status before prescribing the veterinary medicinal product.

The veterinary medicinal product may cause slight reduction in heart rate, respiratory rate and body temperature. As a reduction of body temperature can occur after the administration, the treated animal should be kept at a suitable ambient temperature.

Monitor the cat carefully for any symptoms of respiratory depression and sedation when a CNS depressant is used concomitantly with pregabalin.

The prescribing veterinarian should advise the owner to always inform the attending veterinarian if the veterinary medicinal product has been administered to the cat prior to the veterinary visit.

If the cat spits part of the dose, vomits after treatment, or in case of hypersalivation, do not give another dose.

The effect of the veterinary medicinal product can last approximately 7 hours. In case the cat seems drowsy or shows other signs of exaggerated effects after treatment administration, keep the cat indoors and do not offer water or feed until the cat has fully recovered.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Exposure to pregabalin may cause adverse effects such as dizziness, tiredness, ataxia, blurred vision and headache.

Avoid skin, eye or mucosal contact. Thoroughly wash hands immediately after administration of the veterinary medicinal product.

In case of accidental eye or mucosal contact, flush with water. Seek medical advice if symptoms (dizziness, tiredness, ataxia or blurred vision) occur.

In case of skin contact, wash with soap and water. Remove contaminated clothing.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. Do not drive as tiredness may occur.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Cats:

Common (1 to 10 animals / 100 animals treated):	Emesis Ataxia, Sedation, Proprioception abnormality Lethargy
Uncommon (1 to 10 animals / 1 000 animals treated):	Leucopenia Muscle tremor, Mydriasis Anorexia, Weight loss
Rare (1 to 10 animals / 10 000 animals treated):	Hypersalivation ¹

¹ Typically, clinical signs are mild and transient.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy, lactation and fertility

Laboratory studies in rats and rabbits have shown evidence of embryofetotoxic and maternotoxic effects when pregabalin is administered repeatedly at high doses ($\geq 1\ 250$ mg/kg/day). The safety of the veterinary medicinal product has not been established in breeding animals or during pregnancy and lactation in the target species. Use only according to the benefit-risk assessment by the responsible veterinarian.

3.8 Interaction with other medicinal products and other forms of interaction

The use of other central nervous system depressants is expected to potentiate the effects of pregabalin and therefore an appropriate dose adjustment should be made.

3.9 Administration routes and dosage

Oral use.

The veterinary medicinal product is administered orally as a single dose of 5 mg/kg bodyweight (bw) (0.1 ml/kg bw) approximately 1.5 hours before the start of the transportation/planned veterinary visit.

The veterinary medicinal product can be administered either directly into the mouth or mixed with a small amount of food. Large amounts of food may delay the onset of effect.

Use the oral syringe provided in the package for administration of the veterinary medicinal product.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Safety following repeated administration for 6 consecutive days and at up to 5 times the recommended treatment dose was investigated in an overdose study.

Signs related to motor coordination (abnormal gait, limited usage of hind limbs/paws, uncoordinated behaviour, ataxia), somnolence (decreased activity, closed eyes, lying on side, dilated pupils, decreased body temperature and depression), vomiting and salivation were observed at greater frequency, severity and duration of the signs with doses of 15 mg/kg and 25 mg/kg than that observed at the recommended dose rate of 5 mg/kg bodyweight. Loss of consciousness was noted in one out of eight cats at 25 mg/kg.

If decrease in body temperature occurs, the cat should be kept warm.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Not applicable.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code: QN02BF02

4.2 Pharmacodynamics

Pregabalin binds to the auxiliary subunit (alpha2-delta protein) of voltage-gated calcium channels in the central nervous system thereby reducing the release of various neurotransmitters (glutamate and monoaminergic neurotransmitters) and producing its anxiolytic effect.

4.3 Pharmacokinetics

Absorption

Pregabalin is rapidly absorbed after oral administration in cats. The C_{max} in plasma was 10.1 µg/ml and occurred at 0.5–1.0 hours after administration of 5 mg/kg bodyweight into the mouth of cats in fasted state. The area under plasma concentration-time curve (AUC_{0-24h}) in fasted state was 129 µg*h/ml. The mean absolute oral bioavailability of pregabalin was 94.3 %. After re-dosing of 5 mg/kg at 24 hours, the exposure, in terms of C_{max} , AUC_{0-24h} , and $t_{1/2}$, was comparable with the exposure following single dosing. No significant differences were noted in overall absorption, expressed as plasma C_{max} and AUC , after administration of pregabalin into the mouth under different feeding regimes.

Distribution

Pregabalin has a relatively large volume of distribution. After intravenous bolus administration, the volume of distribution at the steady state (V_{ss}) was 0.4 l/kg. Pregabalin is not known to bind to plasma proteins in mice, rats, monkeys or humans. This has not been studied in cats.

Metabolism and elimination

Pregabalin is quite slowly eliminated from the body of cats. Total plasma clearance was 0.03 l/h/kg. The mean half-life of elimination from circulation was 12.3 hours after intravenous administration of 2.5 mg/kg and 14.7 hours after oral administration of 5 mg/kg.

Elimination of the parent compound as well as the methylation metabolite from circulation occurs almost exclusively by renal excretion in rats, monkeys and humans. In dogs, approximately 45% of the pregabalin dose is excreted in urine as N-methyl metabolite. This has not been studied in cats.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

Not applicable.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

Shelf life after first opening the immediate packaging (removal of the cap): 6 months.

Once opened, the bottle should be stored in a refrigerator but may be stored for short periods of time (up to 1 month in total) at or below 25 °C.

5.3 Special precautions for storage

Store in a refrigerator (2 °C – 8 °C).

5.4 Nature and composition of immediate packaging

A clear Type III glass bottle containing 2 ml of veterinary medicinal product. The bottle is closed with a polypropylene child-resistant closure and a high-density polyethylene liner integrated with a low-density polyethylene adapter. A 1 ml low-density polyethylene oral syringe is included in the box. The syringe is graduated in increments of 0.1 ml.

Pack size: 1 bottle and a syringe in a cardboard box.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Orion Corporation

7. MARKETING AUTHORISATION NUMBER

EU/2/21/273/001

8. DATE OF FIRST AUTHORISATION

Date of first authorisation: 13/07/2021

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

23/01/2025

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

ANNEX II

OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

None

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

CARTON

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Bonqat 50 mg/ml oral solution

2. STATEMENT OF ACTIVE SUBSTANCES

Each ml contains 50 mg pregabalin.

3. PACKAGE SIZE

2 ml
1 oral syringe

4. TARGET SPECIES

Cats.



5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Oral use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}
Once opened use within 6 months.

9. SPECIAL STORAGE PRECAUTIONS

Store in a refrigerator.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”
--

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”
--

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Orion Corporation

14. MARKETING AUTHORISATION NUMBERS
--

EU/2/21/273/001

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS BOTTLE (GLASS)
--

1. NAME OF THE VETERINARY MEDICINAL PRODUCT
--

Bonqat



2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

50 mg/ml

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

Once opened use within 6 months.

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Bonqat 50 mg/ml oral solution for cats

2. Composition

Each ml contains:

Active substance:

Pregabalin 50 mg

Excipient:

Sodium benzoate (E211) 2 mg

Clear, colourless to slightly reddish solution.

3. Target species

Cats.



4. Indications for use

Alleviation of acute anxiety and fear associated with transportation and veterinary visits.

5. Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

6. Special warnings

Special precautions for safe use in the target species:

The safety of the veterinary medicinal product has not been established in cats weighing less than 2 kg, younger than 5 months and older than 15 years. Use only according to the benefit-risk assessment by the responsible veterinarian.

The safety of the veterinary medicinal product has only been established in healthy animals or those with mild systemic illness. It has not been established in animals with moderate or severe systemic disease e.g. moderate or severe renal, liver, or cardiovascular disease. Use only according to the benefit-risk assessment by the responsible veterinarian.

The cat's health status needs always to be assessed by the veterinarian before prescribing the veterinary medicinal product.

The veterinary medicinal product may cause slight decrease in heart rate, respiratory rate and body temperature. As a decrease of body temperature can occur after the administration, the treated animal should be kept at a suitable ambient temperature.

Monitor the cat carefully for any symptoms of sleepiness and respiratory depression if the veterinarian informs that another medicine causing central nervous system depression has been used concomitantly with the veterinary medicinal product.

The animal owner should be advised by the prescribing veterinarian to always inform the attending veterinarian if the veterinary medicinal product has been administered to the cat prior to the veterinary visit.

If the cat spits part of the dose, vomits after treatment, or in case of excessive salivation, do not give another dose.

The effect of the veterinary medicinal product can last approximately 7 hours. In case the cat seems drowsy or shows other signs of exaggerated effects after treatment administration, keep the cat indoors and do not offer water or feed until the cat has fully recovered.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Exposure to the veterinary medicinal product may cause adverse effects such as dizziness, tiredness, balance problems, blurred vision and headache.

Avoid skin, eye or mucosal contact. Thoroughly wash hands immediately after administration of the veterinary medicinal product.

In case of accidental eye or mucosal contact, flush with water. Seek medical advice if symptoms (dizziness, tiredness, balance problems or blurred vision) occur.

In case of skin contact, wash with soap and water. Remove contaminated clothing.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. Do not drive as tiredness may occur.

Special precautions for the protection of the environment:

Not applicable.

Pregnancy and lactation:

Laboratory studies in rats and rabbits have shown evidence of harmful effects during pregnancy when pregabalin is administered repeatedly at very high doses (≥ 250 -fold the recommended dose for cats). The safety of the veterinary medicinal product has not been established during pregnancy and lactation in cats. Use only according to the benefit-risk assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:

The use of other central nervous system depressants is expected to potentiate the effects of pregabalin and therefore an appropriate dose adjustment should be made by the prescribing veterinarian.

Overdose:

Safety following repeated administration for 6 consecutive days and at up to 5 times the recommended treatment dose was investigated in an overdose study. Overdose (3- and 5-fold higher than the recommended dose) can cause signs related to problems with balance, tiredness, vomiting and salivation at greater frequency, severity and duration than the adverse reactions observed at the recommended dose. On rare occasions loss of consciousness can be seen at the 5-fold dose.

If decrease in body temperature occurs, the cat should be kept warm.

7. Adverse events

Cats:

Common (1 to 10 animals / 100 animals treated):	Vomiting (Emesis) Incoordination (Ataxia), Sedation, Sense of movement/position abnormality (Proprioception abnormality) Lethargy
Uncommon (1 to 10 animals / 1 000 animals treated):	Low white blood cell count (Leucopenia) Muscle tremor, Dilated pupils (Mydriasis) Loss of appetite (Anorexia), Weight loss
Rare (1 to 10 animals / 10 000 animals treated):	Hypersalivation ¹

¹ Typically, clinical signs are mild and transient.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}

8. Dosage for each species, routes and method of administration

The recommended dose is 0.1 ml/kg bodyweight. Administer the veterinary medicinal product orally.

9. Advice on correct administration

Give Bonqat approximately 1.5 hours before the start of the transportation/planned veterinary visit.

The veterinary medicinal product can be administered either directly into the mouth or mixed with small amount of food. Large amounts of food may delay the onset of effect. Use the oral syringe provided in the package for administration of the veterinary medicinal product.

See the detailed instructions for administration at the end of this leaflet.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

Store in a refrigerator (2 °C – 8 °C).

Do not use this veterinary medicinal product after the expiry date which is stated on the label and carton after Exp. The expiry date refers to the last day of that month.

Shelf life after first opening the bottle in a refrigerator: 6 months.

Once opened the bottle should be stored in a refrigerator but may be stored for short periods of time (up to 1 month in total) at or below 25 °C.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

EU/2/21/273/001

Pack size:

1 bottle (2 ml) and a syringe (1 ml) in a cardboard box.

15. Date on which the package leaflet was last revised

{DD/MM/YYYY}

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

16. Contact details

Marketing authorisation holder:

Orion Corporation
Orionintie 1
FI-02200 Espoo
Finland

Manufacturer responsible for batch release:

Orion Corporation Orion Pharma
Tengströminkatu 8
FI-20360 Turku
Finland

Local representatives and contact details to report suspected adverse reactions:

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

België/Belgique/Belgien

V.M.D. nv
Hoge Mauw 900
BE-2370 Arendonk
Tél/Tel: +32 14 67 20 51

Česká republika

Orion Pharma s.r.o.
Na strži 2102/61a
CZ-140 00 Praha
Tel: +420 227 027 263

Danmark

Orion Pharma A/S
Ørestads Boulevard 73
DK-2300 København S
Tlf: +45 86 14 00 00

Deutschland

TVM Tiergesundheits GmbH
Reuchlinstrasse 10–11
DE-10553 Berlin
Tel: +49 30 23 59 23 200

Eesti

Orion Pharma UAB
Ukmergės g. 126
08100 Vilnius
Leedu
Tel: +370 5 2769 499

Ελλάδα

Ελάνκο Ελλάς Α.Ε.Β.Ε.
Λεωφόρος Μεσογείων 335
EL-152 31 Χαλάνδρι, Αττική
Τηλ.: +30 6946063971

España

Dômes Pharma Iberia SL
Edificio Net Pharma
Ctra Fuencarral 22
ES-28108 Alcobendas, Madrid
Tel: +34 913 301 651

France

Laboratoires Biové
3 Rue de Lorraine
FR-62510 Arques
Tél: +33 3 21 98 21 21

Lietuva

Orion Pharma UAB
Ukmergės g. 126
LT-08100 Vilnius
Tel: +370 5 2769 499

Luxembourg/Luxemburg

V.M.D. nv
Hoge Mauw 900
2370 Arendonk
Belgique
Tél/Tel: +32 14 67 20 51

Magyarország

Orion Pharma Kft.
Pap Károly u. 4–6
HU-1139 Budapest
Tel.: +36 1 2370603

Nederland

Alivira NV
Kolonel Begaultlaan 1a
3012 Leuven
België
Tel: +32 16 84 19 79

Norge

Orion Pharma AS Animal Health
Postboks 4366 Nydalen
NO-0402 Oslo
Tlf: +47 40 00 41 90

Österreich

VetViva Richter GmbH
Durisolstrasse 14
A-4600 Wels
Tel.: +43 664 8455326

Polska

Orion Pharma Poland Sp. z o.o.
ul. Fabryczna 5A
PL-00-446 Warszawa
Tel.: +48 22 833 31 77

România

Orion Pharma Romania srl
B-dul T. Vladimirescu nr 22
RO-050883, București
Tel: +40 31845 1646

Hrvatska

Iris Farmacija d.o.o.
 Bednjanska 12
 HR-10000 Zagreb
 Tel: +385 (0)91 2575 785

Ireland

Royal Veterinary Supplies Ltd.
 Unit 5, Block 13 Oaktree Business Park
 IE-C15 WK2E Trim, Co.Meath
 Tel: +353 46 9484665

Italia

Alivira Italia S.R.L.
 Corso della Giovecca 80
 IT-44121 Ferrara
 Tel: +39 3482322639

Κύπρος

Ελάνκο Ελλάς Α.Ε.Β.Ε.
 Λεωφόρος Μεσογείων 335
 152 31 Χαλάνδρι, Αττική
 Ελλάδα
 Τηλ.: +30 6946063971

Latvija

Orion Pharma UAB
 Ukmergēs g. 126
 08100 Vilnius
 Lietuva
 Tel: +370 5 2769 499

Ísland**Malta****Portugal****Република България**

Tel: + 358 10 4261

Slovenija

IRIS d.o.o.
 Cesta v Gorice 8
 SI-1000 Ljubljana
 Tel: +386 01 200 66 54

Slovenská republika

Orion Pharma s.r.o.
 Na strži 2102/61a
 140 00 Praha
 Česko
 Tel: +420 227 027 263

Suomi/Finland


Orion Pharma Eläinlääkkeet
 PL/PB 425
 FI-20101 Turku/Åbo
 Puh/Tel: +358 10 4261

Sverige


Orion Pharma AB, Animal Health
 Golfvägen 2
 SE-182 31 Danderyd
 Tel: +46 8 623 64 40

United Kingdom (Northern Ireland)

Royal Veterinary Supplies Ltd.
 Unit 5, Block 13 Oaktree Business Park
 Trim, Co. Meath C15 WK2E
 Ireland
 Tel: +353 46 9484665



17. Other information**INSTRUCTIONS FOR ADMINISTRATION:****1. REMOVE CAP**

Remove the cap from the bottle (press down and twist). Save the cap for reclosure.



2. CONNECT SYRINGE

Push the plunger to the bottom of the syringe barrel to squeeze all the air out of the syringe. Push the syringe tightly into the adapter located at the top of the bottle. Use only the syringe provided with the product.



3. SELECT DOSE

Turn the bottle with the syringe in place upside down. Pull the plunger out until the black line of correct dose (ml) (prescribed by your veterinarian) can be seen under the grip plate of the syringe barrel.

If the cat weighs more than 10 kg, the total dose will need to be calculated and given in two separate doses as the syringe holds maximally only 1.0 ml of solution.


Don't leave the filled dosing syringe unattended while preparing the cat for administration.



4. ADMINISTER DOSE

Gently place the syringe in the mouth of the cat and administer the dose to the base of the tongue by gradually pressing the plunger until the syringe is empty.

If the dose cannot be given directly into mouth the product can be mixed with small amount of cat's favourite food. Do not leave additional food available for the cat after the dose has been administered as extra food may delay the onset of effect .



5. BACK TO PACKAGE

Replace the cap and rinse the syringe with water after use. Return the syringe and bottle to the cardboard box and store them in the refrigerator.